Incretin-based therapies for type 2 diabetes mellitus

By J. Lovshin, D. J. Drucker. Nature Reviews Endocrinology, 2009

725 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/52920e8fc54e1ce9a26fb237442518baaee7a071

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Josephine M. Egan
2. Wook Kim

In Molecular Biology

1. Josephine M. Egan
2. Wook Kim

Citations in the corpus

• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease (2011, background): “Currently, the GLP-1 receptor agonists exendin-4 (Exenatide, Byetta) and liraglutide (Victoza) are approved for treatment of T2DM (Lovshin and Drucker, 2009).”
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “Metformin actually increases incretin secretion (Chia and Egan, 2008), and this factor probably explains why the addition of DPP4 inhibitors to metformin therapy has more of an effect on reductions in HbA1c than would be expected from simply adding together the effects of each as a monotherapy:…”